Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Issue 1 (2nd January 2018)

• Record Type: Journal Article
• Authors: Bello, Nicholas T.; Yeomans, Bryn L
• Is Part Of: Expert opinion on drug safety. Volume 17:Issue 1(2018)
• Page Start: 17
• Page End: 23
• Publication Date: 2018-01-02
• Subjects: Prozac -- bulimic -- loss of control -- therapeutic -- vyvanse; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2018.1395854
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Eating disorders represent a set of psychiatric illnesses with lifelong complications and high relapse rates. Individuals with eating disorders are often stigmatized and clinicians have a limited set of treatments options. Pharmacotherapy has the potential to improve long term compliance and patient commitment to treatment for eating disorders. Areas covered : This review will examine the efficacy and safety profile of the FDA-approved medications for the treatment of bulimia nervosa (BN) and binge eating disorder (BED). This will include the evaluation of fluoxetine for BN, and lisdexamfetamine for BED. Safety information will be review from randomized control trials (RCT), open label trials, and case reports. Expert opinion : Fluoxetine for BN and lisdexamfetamine for BED are relatively safe and well-tolerated. Despite these properties, these two medications represent a limited arsenal for the pharmacological treatment of eating disorders. Thus, more research-based strategies are needed to develop safe, effective, and more targeted therapies for eating disorders.